Cancer Researcher Brews Beer That Acts as a Vaccine Against Virus

A researcher at the National Cancer Institute, Christopher Buck, has developed a unique approach to vaccine creation by brewing a beer that offers immunity against the BK virus, also known as human polyomavirus. Buck’s home-brewed beverage represents an innovative experiment in vaccine development, challenging conventional regulatory pathways set by the Food and Drug Administration (FDA).

Buck’s brewing process combines his expertise in cancer research with a creative method of vaccine delivery. By engineering brewer’s yeast to produce a protein that encapsulates the BK virus, he aims to trigger an immune response within the body. His hazy beer, made using a Flash Hefeweizen kit and hop tea, serves as both a personal experiment and a potential model for future edible vaccines.

Infection with human polyomavirus 1 is common, with about 90 percent of individuals developing antibodies by age 10. While the virus typically poses little risk to those with healthy immune systems, it can reactivate in organ transplant recipients, leading to complications. Buck’s vaccine could offer a preventive measure for this vulnerable population.

Buck’s experimentation involved drinking one to two pints of his homemade beer over several days, followed by booster doses. He reports no adverse effects and confirms that his immune system produced antibodies against multiple strains of the BK virus. He emphasizes that these findings pave the way for the development of inexpensive vaccines delivered through everyday food products.

Despite the unconventional nature of his project, Buck asserts that his beer would not be subject to FDA regulations for vaccines. The ingredients are already recognized as safe for consumption and are part of the food supply. To clarify his intent, Buck established the Gusteau Research Corporation, a nonprofit where he is the sole employee, to separate his research from his professional work. His brother founded Remy LLC to market food-grade engineered yeast products.

Buck’s initiative comes at a time when public trust in traditional vaccines is fluctuating. He notes, “In the United States, there has been a growing movement to downplay the safety and efficacy of traditional vaccines.” This shift has prompted discussions about regulatory frameworks and the potential for DIY solutions in vaccine development.

By advocating for food-based vaccines, Buck suggests that individuals could regain control over their health decisions. He encourages fellow scientists to explore the applicability of his polyomavirus vaccine to other viral threats, such as bird flu and persistent COVID-19 variants.

In Buck’s view, the future of vaccine development may involve simpler, food-based solutions that leverage market dynamics and scientific scrutiny to counteract regulatory overreach. He draws inspiration from the film Ratatouille, where chef Auguste Gusteau famously stated, “Anyone can cook—but only the fearless can be great,” encouraging innovation and creativity in scientific endeavors.

As the landscape of vaccine development continues to evolve, Buck’s experiment highlights both the potential and challenges of integrating culinary practices with immunization strategies, opening doors for further exploration in the field.